Neuropathic Pain

L

ateral Pharma is repurposing LAT8881 for treatment of neuropathic pain, osteoarthritis and other painful chronic diseases.  Lateral has worked with external CROs and collaborators using different approaches to investigate analgesic properties of LAT8881 and other backup LAT peptides:

  • Prof David Spanswick at Pacific Discovery Services (PDS)/Neurosolutions and Charles River Labs have been key collaborators for the pain studies in the following model systems :
  • Ex vivo spinal cord slice model (DRG) preparations from rats subject to chronic nerve constriction (Chung model) directly monitoring neuronal activity with electrophysiology
  • In vivo behavioural models of pain monitoring mechanical or thermal hyperalgesia or other pain responses mostly conducted by Pacific Discovery Services (PDS):
    • Chung model of chronic nerve constriction injury – studies conducted by PDS
    • Chemotherapy-induced neuropathic pain model – two studies, one conducted by PDS and one by Charles River Laboratories
    • Streptozotocin Diabetic neuropathy – one study conducted by PDS
    • Reserpine model of fibromyalgia – one study conducted by PDS
    • Post operative surgical pain – one study conducted by PDS
    • Models of osteoarthritis, (1) Intra-articular Collagenase – one study conducted by Prof Kwon of Daegu Catholic University Medical Center and (2) Mono-iodo acetate – two studies, one conducted by PDS and one by Charles River Laboratories
Lateral-Pharma